155 related articles for article (PubMed ID: 25531195)
1. Lung injury associated with mTOR inhibitors (sirolimus and everolimus).
Conti V; Grazia M; Romagnoli M; Poletti G; Cristino S; Ciliberti G; Piciucchi S; Mosconi G; Poletti V
Minerva Urol Nefrol; 2014 Dec; 66(4):283-5. PubMed ID: 25531195
[No Abstract] [Full Text] [Related]
2. Comparative analysis of adverse events requiring suspension of mTOR inhibitors: everolimus versus sirolimus.
Sánchez-Fructuoso AI; Ruiz JC; Pérez-Flores I; Gómez Alamillo C; Calvo Romero N; Arias M
Transplant Proc; 2010 Oct; 42(8):3050-2. PubMed ID: 20970607
[TBL] [Abstract][Full Text] [Related]
3. Interstitial pneumonitis as an adverse reaction to mTOR inhibitors.
Molas-Ferrer G; Soy-Muner D; Anglada-Martínez H; Riu-Viladoms G; Estefanell-Tejero A; Ribas-Sala J
Nefrologia; 2013; 33(3):297-300. PubMed ID: 23712219
[TBL] [Abstract][Full Text] [Related]
4. Proteinuria associated with mTOR inhibitors after kidney transplant.
Guney M; Sahin G; Yilmaz B; Canbakan M; Gucun M; Kayatas K; Eren P; Titiz I
Exp Clin Transplant; 2014 Dec; 12(6):539-42. PubMed ID: 25489805
[TBL] [Abstract][Full Text] [Related]
5. Total recall of radiotherapy with mTOR inhibitors: a novel and potentially frequent side-effect?
Bourgier C; Massard C; Moldovan C; Soria JC; Deutsch E
Ann Oncol; 2011 Feb; 22(2):485-6. PubMed ID: 21278224
[No Abstract] [Full Text] [Related]
6. [Everolimus and azoospermia, a causal relationship? About one case in a renal transplant patient].
Wetzstein M; Weestel PF; Choukroun G
Nephrol Ther; 2014 Feb; 10(1):44-5. PubMed ID: 24374233
[TBL] [Abstract][Full Text] [Related]
7. Pneumonitis associated with mammalian target of rapamycin inhibitors in renal transplant recipients: a single-center experience.
Errasti P; Izquierdo D; Martín P; Errasti M; Slon F; Romero A; Lavilla FJ
Transplant Proc; 2010 Oct; 42(8):3053-4. PubMed ID: 20970608
[TBL] [Abstract][Full Text] [Related]
8. Everolimus- and temsirolimus-associated enteritis: report of three cases.
Parithivel K; Ramaiya N; Jagannathan JP; O'Regan K; Krajewski K; Fisher D; Choueiri TK; Jacobsen E
J Clin Oncol; 2011 May; 29(14):e404-6. PubMed ID: 21357780
[No Abstract] [Full Text] [Related]
9. [Hyperglycaemia during treatment with everolimus].
Opdam FL; Huitema AD; Beijnen JH; Schellens JH
Ned Tijdschr Geneeskd; 2014; 158():A7544. PubMed ID: 25115206
[TBL] [Abstract][Full Text] [Related]
10. Severe everolimus-associated pneumonitis in a renal transplant recipient.
Alexandru S; Ortiz A; Baldovi S; Milicua JM; Ruíz-Escribano E; Egido J; Plaza JJ
Nephrol Dial Transplant; 2008 Oct; 23(10):3353-5. PubMed ID: 18658177
[TBL] [Abstract][Full Text] [Related]
11. Pneumocystis jirovecii pneumonia in everolimus-treated renal cell carcinoma.
Loron MC; Grange S; Guerrot D; Di Fiore F; Freguin C; Hanoy M; Le Roy F; Poussard G; Etienne I; Legallicier B; Pfister C; Godin M; Bertrand D
J Clin Oncol; 2015 Mar; 33(8):e45-7. PubMed ID: 24638002
[No Abstract] [Full Text] [Related]
12. Differentiating the mTOR inhibitors everolimus and sirolimus in the treatment of tuberous sclerosis complex.
MacKeigan JP; Krueger DA
Neuro Oncol; 2015 Dec; 17(12):1550-9. PubMed ID: 26289591
[TBL] [Abstract][Full Text] [Related]
13. Efficacy of re-challenging metastatic renal cell carcinoma with mTOR inhibitors.
Roca S; Quivy A; Gross-Goupil M; Bernhard JC; De Clermont H; Ravaud A
Acta Oncol; 2011 Oct; 50(7):1135-6. PubMed ID: 21726178
[No Abstract] [Full Text] [Related]
14. Everolimus-related organizing pneumonia: a report establishing causality.
Frija J; Joly D; Knebelmann B; Dusser D; Burgel PR
Invest New Drugs; 2012 Jun; 30(3):1244-7. PubMed ID: 21188465
[No Abstract] [Full Text] [Related]
15. mTOR inhibitors and autosomal dominant polycystic kidney disease.
Grantham JJ; Bennett WM; Perrone RD
N Engl J Med; 2011 Jan; 364(3):286-7; author reply 287-9. PubMed ID: 21247328
[No Abstract] [Full Text] [Related]
16. Risk evaluation and mitigation strategies: a focus on the mammalian target of rapamycin inhibitors.
Gabardi S
Prog Transplant; 2013 Mar; 23(1):55-7. PubMed ID: 23448821
[TBL] [Abstract][Full Text] [Related]
17. mTOR inhibitors and autosomal dominant polycystic kidney disease.
Braun WE
N Engl J Med; 2011 Jan; 364(3):287; author reply 287-8. PubMed ID: 21247326
[No Abstract] [Full Text] [Related]
18. Everolimus-induced severe pulmonary toxicity with diffuse alveolar hemorrhage.
Junpaparp P; Sharma B; Samiappan A; Rhee JH; Young KR
Ann Am Thorac Soc; 2013 Dec; 10(6):727-9. PubMed ID: 24364783
[No Abstract] [Full Text] [Related]
19. [Rechallenge of everolimus for metastatic renal cell carcinoma after recovery from grade 3 interstitial lung disease: a case report].
Utsunomiya N; Kono Y; Matsumoto K; Matsumoto T; Nakagawa A; Tsunemori H; Okada T; Muguruma K; Kawakita M
Hinyokika Kiyo; 2014 Jan; 60(1):25-8. PubMed ID: 24594769
[TBL] [Abstract][Full Text] [Related]
20. mTOR inhibitors and autosomal dominant polycystic kidney disease.
Levey AS; Stevens LA
N Engl J Med; 2011 Jan; 364(3):287; author reply 287-9. PubMed ID: 21247327
[No Abstract] [Full Text] [Related]
[Next] [New Search]
